GlobalData on MSN14d
AbbVie and Simcere Zaiming link to develop trispecific antibodyThe humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...
NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...
(RTTNews) - AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement to advance SIM0500, an investigational drug ...
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
The Big Pharma is handing China’s Simcere Zaiming an undisclosed upfront payment with the potential of up to $1.05 billion in milestone payments for a phase 1-stage trispecific antibody.
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback